

Product Brochure
Clindamycin 300 Mg Injection
₹ 129/Piece
| Strength | 300 mg/2 ml |
| Packaging Size | 2 ml |
| Brand | BURGEON HEALTH SERIES |
| Composition | Clindamycin 300 mg |
| Route of Administration | IV/IM |
| Packaging Type | Glass ampoule |
| Quantity Unit | Vial |
| Shelf Life | 24 months |
| Prescription Type | Prescription |
| Country of Origin | Made in India |
| Dose | 300mg |
| Usage | Hospital |
| Form | Injection |
| Pack Type | Box |
| Availability | In Stock |
Find related categories
Shipping Information
| Price | Excluding all taxes |
| Shipping | As per delivery location |
Product Image


About the Company
- GST Registration Date
- Mar 2022
- Legal Status of Firm
- Limited Company
- Nature of Business
- Trader - Wholesaler/Distributor
- Number of Employees
- Upto 10 People
- Annual Turnover
- 1.5 - 5 Cr
- IndiaMART Member Since
- Mar 2020
- GST
- 04**********1ZU
Burgeon Health Series Pvt. Ltd. is a well known pharma company that provides pcd pharma franchise services in India. The main activity of our firm as a pcd pharma company is focusing on the Manufacturing and marketing of good quality medicines. We support all our partners regarding delivery terms and costs and guarantee full promotion for their business to expand effectively. These principles make us stalwart to be one of the fastest growing pharma franchise companies in the critical care segment.
Being a trusted pcd pharma company in Chandigarh, Burgeon Health Series is offering DCGI approved 300+ pharma products to their associates. The company is also offering monopoly marketing rights for all their products in Pan India. Their products range includes Tablets, Capsules, Critical Care Injections, Ointments, etc.
Being a trusted pcd pharma company in Chandigarh, Burgeon Health Series is offering DCGI approved 300+ pharma products to their associates. The company is also offering monopoly marketing rights for all their products in Pan India. Their products range includes Tablets, Capsules, Critical Care Injections, Ointments, etc.









